Tower Research Capital LLC (Trc) Erasca, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Erasca, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 11,147 shares of ERAS stock, worth $28,759. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,147
Previous 21,533
48.23%
Holding current value
$28,759
Previous $27,000
11.11%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ERAS
# of Institutions
155Shares Held
213MCall Options Held
281KPut Options Held
32K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$58.6 Million2.1% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.2MShares$52.2 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$46.1 Million5.91% of portfolio
-
Logos Global Management LP San Francisco, CA15.2MShares$39.1 Million3.82% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$37.4 Million0.95% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $315M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...